Alle Studien
Aktiv, aber nicht rekrutierendPHASE2INTERVENTIONELL

A Study of Intrathecal SHP611 in Children With Metachromatic Leukodystrophy

This study is investigating a new medicine called SHP611 for children diagnosed with Metachromatic Leukodystrophy (MLD). The main goal is to find out if SHP611, when injected directly into the fluid surrounding the brain and spinal cord, can help children keep their ability to walk and move around for a longer time. Researchers will also be observing how this medicine affects a child's movement and speech. Another important aim is to understand how well children tolerate the medicine and if there are any side effects. Children taking part in the study will receive SHP611 for around two years, with the possibility of continuing treatment for longer if the study shows it to be helpful.

Auf einen Blick

Status
Aktiv, aber nicht rekrutierend
Phase
PHASE2
Sponsor
Shire
Einschreibeziel
36
Starten
13 May 2019
Geschätzte Fertigstellung
01. Mai 2026

Ergebnisse

Ergebnisse dieser Studie

Veröffentlicht June 2024

Die Ergebnisse dieser Studie wurden veröffentlicht.

Hauptausgang
Percent Probability of Free of Loss of Locomotion in the Last Time Interval Up to 2 Years (Week 106) Based on GMFC-MLD for SHP611 Group A and GLIA-MLD Matched External Control
Loss of locomotion was estimated using interval censoring survival analysis. Survival probability free of loss of locomotion based on GMFC-MLD was estimated up to Week 106 (or two years), with associated 2-sided 95 percent (%) confidence interval (CI). GMFC-MLD scale consists of 7 categories, scores ranging from 0 (walking without support with quality of performance normal for age) to 6 (loss of any locomotion as well as loss of any head and trunk control). Higher scores mean a worse outcome. The data was reported in terms of Mean as survival function was quantified using a weighted average of percentage of participants not reaching the event of interest, with weights derived from the relative size of treated and control units in the strata used for the stratified log-rank test in the primary analysis.
Vollständige Ergebnisse im Register

Worum geht es in dieser Studie?

This study is looking at a new approach to treating Metachromatic Leukodystrophy (MLD) in children. MLD is a rare genetic condition that affects the brain and nervous system, making it difficult for children to move, speak, and learn over time. Currently, there isn't a cure, so researchers are constantly working to find treatments that can help.

The medicine being tested in this study is called SHP611. It's given through an injection directly into the fluid that surrounds the brain and spinal cord, which is known as 'intrathecal' delivery. This method is used because it helps the medicine reach the areas where it's needed most to hopefully slow down the progression of the disease.

The main purpose of this study is to see if SHP611 can help children with MLD keep their ability to move around independently for a longer period. The researchers will also be carefully monitoring other important aspects of a child's health, such as their ability to speak and their overall movement. It's also very important to find out if SHP611 is safe and well-tolerated by children.

Wichtige Erkenntnisse

  • This study explores a new medicine (SHP611) for children with MLD.
  • The medicine is given by injection into the spinal fluid.
  • The main goal is to help children keep their ability to move for longer.
  • Researchers will also check its effects on speech and safety.
  • Participation lasts about two years, with possible extension.

Wer könnte berechtigt sein?

To join this study, children must have a formal diagnosis of Metachromatic Leukodystrophy (MLD). This means tests would have shown specific changes in their blood (low ASA activity) and urine (high sulfatides).

Children need to be within a specific age range, generally between 6 months and 6 years old, depending on their specific MLD symptoms. They must also have certain levels of symptoms. For some, this means having difficulty walking due to MLD by 2 and a half years old. Others might be very young (6 to under 18 months), showing very few symptoms, but having the same MLD gene changes as an older child in their family. Another group might be between 12 and under 18 months old, showing early MLD symptoms, but having previously been able to walk steadily.

Finally, parents or legal guardians must be able to follow the study schedule and must give their written permission for their child to take part.

Könnte diese Studie für Sie geeignet sein?

Beantworten Sie diese kurzen Fragen, um zu sehen, ob Sie möglicherweise berechtigt sind. Dies ist nur ein Leitfaden – das Forschungsteam trifft die endgültige Entscheidung.

  1. Does my child have a confirmed MLD diagnosis?
  2. Is my child between 6 months and 6 years old (age varies by specific MLD symptoms)?
  3. Does my child meet certain criteria for MLD symptom severity or progression?
  4. Can I commit to following the study's schedule of appointments and procedures?
  5. Am I able to give informed consent for my child to participate?
Beantworten Sie jede Frage, um Ihr Ergebnis zu sehen.

Was beinhaltet die Teilnahme?

If your child takes part in this study, they will receive the study medicine, SHP611, for about two years. There might be a chance to continue receiving the medicine for a longer time after this initial period. The medicine will be given by injection directly into the fluid around the brain and spinal cord.

Throughout the study, there will be regular visits to the clinic so that doctors can carefully monitor your child's health, track their movement and speech, and check for any changes or side effects. These assessments help the research team understand how the medicine is working and how your child is responding. You'll be given a detailed schedule of visits and what each visit will involve.

Potenzielle Risiken und Vorteile

Taking part in any medical study has both potential benefits and risks. While SHP611 is being studied to see if it can help slow down the progression of MLD and improve movement and speech, there's no guarantee it will work for every child. There might also be side effects from the medicine or the procedures, like the spinal injections. The study team will explain all known risks to you. You have the right to withdraw your child from the study at any time, for any reason, without affecting their future medical care.

Locations (30)

  • Los Angeles Biomedical Research Institute at Harbor-UCLA
    Verifizierte Postleitzahl
    Torrance, Vereinigte Staaten
  • Kinderkrankenhaus Colorado
    Verifizierte Postleitzahl
    Aurora, Vereinigte Staaten
  • Rare Disease Research, LLC
    Verifizierte Postleitzahl
    Atlanta, Vereinigte Staaten
  • Ann & Robert H. Lurie Kinderkrankenhaus von Chicago
    Verifizierte Postleitzahl
    Chicago, Vereinigte Staaten
  • University of Iowa Stead Family Children's Hospital
    Verifizierte Postleitzahl
    Iowa City, Vereinigte Staaten
  • Mayo Clinic - PPDS
    Verifizierte Postleitzahl
    Rochester, Vereinigte Staaten
  • New York University Langone Medical Center
    Verifizierte Postleitzahl
    New York, Vereinigte Staaten
  • Cincinnati Kinderkrankenhaus Medizinisches Zentrum
    Verifizierte Postleitzahl
    Cincinnati, Vereinigte Staaten
  • Children's Hospital of Philadelphia
    Verifizierte Postleitzahl
    Philadelphia, Vereinigte Staaten
  • Children's Hospital of Pittsburgh
    Verifizierte Postleitzahl
    Pittsburgh, United States
  • University of Utah
    Verifizierte Postleitzahl
    Salt Lake City, Vereinigte Staaten
  • Hospital Universitario Austral - PIN
    Nur Stadt
    Ciudad Autónoma Buenos Aires, Argentina

Häufige Fragen

What is Metachromatic Leukodystrophy (MLD)?

MLD is a rare genetic disease that affects the brain and nervous system, leading to problems with movement, speech, and other abilities over time.

What is SHP611?

SHP611 is the experimental medicine being tested in this study. It's hoped it can help children with MLD.

How is SHP611 given?

It's given as an injection into the fluid that surrounds the brain and spinal cord, similar to a lumbar puncture.

Wie lange wird mein Kind an der Studie teilnehmen?

Children will receive the medicine for about two years, and there might be an option for longer treatment.

Is this medicine available to everyone?

No, SHP611 is an investigational medicine, which means it's still being studied and is not yet available outside of clinical trials.

Wie Sie mehr erfahren können

Sprechen Sie immer mit Ihrem Hausarzt oder Spezialisten, bevor Sie sich entscheiden, an einer Studie teilzunehmen.

Diskussion

Community-Diskussion

Bereitgestellt von unserem Forum bei community.patient.info. Bitte seien Sie respektvoll — dies ist kein medizinischer Rat.